New insight into the molecular mechanism of TCM Bufei Huoxue formula for chronic obstructive pulmonary disease based on network pharmacology and experimental verification
Journal of Pharmacy and Pharmacology · 2024
DOI: 10.1093/jpp/rgae071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2024. Verfasst von Yuanying Zhu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of…. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Drugs, Chinese Herbal, Network Pharmacology, Glucosides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, Key Research and Development Project of Shandong Province, Yantai University, China.
Themen: COPD
Abstract (Originalsprache)
Objectives
To unveil the mechanism of the Bufei Huoxue formula (BHF) for chronic obstructive pulmonary disease (COPD) through integrated network pharmacology (NP) and experimental verification.
Methods
LC-MS was first applied to the analysis of both in vitro and in vivo samples from BHF for chemical profiling. Then a ligand library was prepared for NP to reveal the mechanism of BHF against COPD. Finally, verification was performed using an animal model related to the results from the NP. Key findings A ligand library containing 170 compounds from BHF was obtained, while 357 targets related to COPD were filtered to construct a PPI network. GO and KEGG analysis demonstrated that bavachin, paeoniflorin, and demethylation of formononetin were the major compounds for BHF against COPD, which mainly by regulating the PI3K/Akt pathway. The experiments proved that BHF could alleviate lung injury and attenuate the release of TNF-α and IL-6 in the lung and BALF in a dose-dependent manner. Western blot further demonstrated the down-regulated effect of BHF on p-PI3K.
Conclusion
BHF provides a potent alternative for the treatment of COPD, and the mechanism is probably associated with regulating the PI3K/AKT pathway to alleviate inflammatory injury by bavachin, paeoniflorin, and demethylation of formononetin.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Minis…
- Yantai Center for Food and Drug Control, Yantai, 264003, China.
- Department of Pharmacy, Wenzhou People's Hospital, The Third Affiliated Hospital of Shanghai University, The Third Clinical Institute Affiliated to Wenzhou Medical University, Wenzhou, 325099, China.
- School of Chemistry and Chemical Engineering, Yantai University, Yantai 264005, China.
ORCID-Profile: Hui Xu
Förderung
- Natural Science Foundation of Shandong Province
- Key Research and Development Project of Shandong Province
- Yantai University, China
Zitieren
APA
Zhu, Y., Hao, S., Wu, Y., Lin, Y., Liu, X., Luo, T., Zhou, Y., Yang, X., & Xu, H. (2024). New insight into the molecular mechanism of TCM Bufei Huoxue formula for chronic obstructive pulmonary disease based on network pharmacology and experimental verification. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgae071
Vancouver
Zhu Y, Hao S, Wu Y, Lin Y, Liu X, Luo T, et al. New insight into the molecular mechanism of TCM Bufei Huoxue formula for chronic obstructive pulmonary disease based on network pharmacology and experimental verification. Journal of Pharmacy and Pharmacology. 2024. doi:10.1093/jpp/rgae071
BibTeX
@article{Zhu2024,
author = {Zhu, Yuanying and Hao, Shengyuan and Wu, Yan and Lin, Yuxian and Liu, Xuecun and Luo, Ting and Zhou, Yubing and Yang, Xin and Xu, Hui},
title = {New insight into the molecular mechanism of TCM Bufei Huoxue formula for chronic obstructive pulmonary disease based on network pharmacology and experimental verification},
journal = {Journal of Pharmacy and Pharmacology},
year = {2024},
doi = {10.1093/jpp/rgae071}
}
EUVIMED